Prospective evaluation of the incidence and risk factors for the development of RPE tears after high- and low-dose ranibizumab therapy
- PMID: 23652578
- DOI: 10.1097/IAE.0b013e31828992f5
Prospective evaluation of the incidence and risk factors for the development of RPE tears after high- and low-dose ranibizumab therapy
Abstract
Purpose: To prospectively determine the incidence and risk factors for retinal pigment epithelial (RPE) tears in eyes with vascularized pigment epithelial detachments (PED) and exudative age-related macular degeneration receiving antivascular endothelial growth factor therapy.
Methods: Eyes were prospectively randomized into 1 of 4 arms: 1) 0.5 mg of ranibizumab monthly for 12 months; 2) 0.5 mg of ranibizumab monthly for 3 months and then pro re nata on the basis of clinical and optical coherence tomography-guided indications; 3) high-dose 2.0 mg of ranibizumab monthly for 12 months; or 4) 2.0 mg of ranibizumab monthly for 3 months and then pro re nata thereafter. All PEDs were measured for height, greatest linear diameter, and surface area at baseline. The incidence of RPE tears in the entire 4-arm cohort was determined at the end of 12 months. Eyes were divided into two groups (tear vs. nontear) and statistically compared to determine risk factors for the development of RPE tear.
Results: Of 37 eyes, a total of 5 developed postranibizumab RPE tears during the course of the study (incidence 14%). Four of the 5 tears occurred in the high-dose 2.0-mg groups. Baseline PED height, surface area, and greatest linear diameter were significantly greater in the group that developed RPE tears versus the nontear group (P = 0.018, 0.031, and 0.048, respectively). There were significantly more eyes with PED height >550 microns in the RPE tear group (4 of 5, 80%) compared with the nontear group (9 of 32, 18%) (P = 0.042). The presence of PED height >550 microns was associated with an increased tear rate from 14% to 31%. Furthermore, retrospective identification of a ring sign or Grade 1 tear at baseline, in addition to PED height >550 microns, was associated with a further increase in the tear rate to 67%.
Conclusion: In this study, the prospective incidence of RPE tears was ∼14%. A baseline PED height >550 microns and presence of a Grade 1 tear, or positive ring sign, were identified as high-risk factors for the subsequent development of an RPE tear.
Similar articles
-
Optical coherence tomography-measured pigment epithelial detachment height as a predictor for retinal pigment epithelial tears associated with intravitreal bevacizumab injections.Retina. 2010 Feb;30(2):203-11. doi: 10.1097/IAE.0b013e3181babda5. Retina. 2010. PMID: 19952998 Clinical Trial.
-
Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular degeneration.Ophthalmology. 2011 Dec;118(12):2447-52. doi: 10.1016/j.ophtha.2011.05.026. Epub 2011 Aug 27. Ophthalmology. 2011. PMID: 21872935 Clinical Trial.
-
Response of vascular pigment epithelium detachment due to age-related macular degeneration to monthly treatment with ranibizumab: the prospective, multicentre RECOVER study.Acta Ophthalmol. 2017 Nov;95(7):683-689. doi: 10.1111/aos.13359. Epub 2017 Jan 13. Acta Ophthalmol. 2017. PMID: 28084038 Clinical Trial.
-
Tears of the retinal pigment epithelium: an old problem in a new era.Retina. 2007 Jun;27(5):523-34. doi: 10.1097/IAE.0b013e3180a032db. Retina. 2007. PMID: 17558312 Review.
-
Retinal pigment epithelium tears: Classification, pathogenesis, predictors, and management.Surv Ophthalmol. 2017 Jul-Aug;62(4):493-505. doi: 10.1016/j.survophthal.2017.03.004. Epub 2017 Mar 21. Surv Ophthalmol. 2017. PMID: 28336128 Review.
Cited by
-
Pigment epithelial tears after ranibizumab injection in polypoidal choroidal vasculopathy and typical age-related macular degeneration.Graefes Arch Clin Exp Ophthalmol. 2015 Dec;253(12):2151-60. doi: 10.1007/s00417-015-2977-3. Epub 2015 Mar 7. Graefes Arch Clin Exp Ophthalmol. 2015. PMID: 25744335
-
Visual outcomes, safety profile and morphometric response of optical coherence tomography biomarkers to ranibizumab biosimilar treatment in neovascular age-related macular degeneration: Real-world evidence.Indian J Ophthalmol. 2021 Jun;69(6):1469-1474. doi: 10.4103/ijo.IJO_2977_20. Indian J Ophthalmol. 2021. PMID: 34011722 Free PMC article.
-
Response to brolucizumab treatment for refractory serous pigment epithelial detachment secondary to polypoidal choroidal vasculopathy.BMC Ophthalmol. 2022 Dec 13;22(1):485. doi: 10.1186/s12886-022-02711-5. BMC Ophthalmol. 2022. PMID: 36514022 Free PMC article.
-
OCT Biomarkers in Neovascular Age-Related Macular Degeneration: A Narrative Review.J Ophthalmol. 2021 Jul 17;2021:9994098. doi: 10.1155/2021/9994098. eCollection 2021. J Ophthalmol. 2021. PMID: 34336265 Free PMC article. Review.
-
A view of the current and future role of optical coherence tomography in the management of age-related macular degeneration.Eye (Lond). 2017 Jan;31(1):26-44. doi: 10.1038/eye.2016.227. Epub 2016 Nov 25. Eye (Lond). 2017. PMID: 27886184 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical